← All Atara Biotherapeutics, INC filings

Atara Biotherapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ATRA
Atara Biotherapeutics, INC
10-K: Atara Biotherapeutics Navigates Manufacturing Hurdles, Pauses CAR-T Programs in Strategic Shift
Atara Biotherapeutics pauses CAR-T programs, focuses on tab-cel amid manufacturing challenges and strategic review.
NASDAQ
ATRA
Atara Biotherapeutics, INC
10-K: Atara Biotherapeutics Expands Global Reach with Amended Commercialization Agreement, Secures Funding for Future Growth
Atara Biotherapeutics has amended its commercialization agreement with Pierre Fabre, expanding its reach to all global markets and securing a $20 million upfront payment, while also navigating financial challenges with workforce reductions.